فهرست نشریات علمی دسترسی آزاد ایران

Introduction: Although ototoxicity and neuropathy are common side effects of cisplatin,there is no evidence of altered olfactory function in cancer patients receiving cisplatinbased chemotherapy. The purpose of this study was to investigate the effect of cisplatin onolfactory function.Materials and Methods: Fifty-eight patients (13 female, and 45 male with a mean age of 54years) who needed to be treated with cisplatin based chemotherapy at our institution wereenrolled in this study. Cisplatin with a dose of 70-100 mg/m2 was administered per cycle indifferent chemotherapy regimens. Olfactory function and audiometery were tested beforebeginning chemotherapy (as baseline). Assessment of olfactory function also was carried outbefore each cycle of cisplatin and finally olfactory test and audiometery was performed at least3 weeks after the last course of cisplatin based chemotherapy.Results: Of 58 patients enrolled in this study, seven patients died due to their cancer and 51patients completed the planned chemotherapeutic treatment. The patients received cisplatin ata cumulative dose of 100-700 mg/m2 (mean cumulative dose: 380 mg/m2) during theirchemotherapy treatment. Hearing impairment was documented in fourteen patients and fourpatients developed hyposmia and one patient anosmia that had no hearing loss. The test scorechanges were not statistically significant but there was a statistically significant correlationbetween drug dose and hearing loss (P=0.039).Conclusion: The results of this study showed that cisplatin has no statistically significanteffect on the sense of smell at doses which cause hearing impairment.